Table 2.

Growth inhibitory effects (GI%) exerted by compounds 15a-k on breast and prostate cancer cells

Compounda	R	BT-474	MDA-MB-231	PC3
SAHA		98.22 ± 1.82b	97.54 ± 1.59b	87.86 ± 7.85b
15a	C6H5	82.32 ± 3.40b	89.60 ± 2.35b,c	63.62 ± 13.55b,c
15b	4-NO2C6H4	65.82 ± 20.06b,c	86.71 ± 3.65b,c	64.32 ± 9.72b,c
15c	3-NO2C6H4	84.14 ± 11.11b	86.79 ± 3.96b,c	74.20 ± 7.61b,c
15d	4-FC6H4	27.68 ± 18.59b,c	74.71 ± 3.43b,c	36.73 ± 18.26b,c
15e	4-BrC6H4	74.75 ± 17.70b,c	84.68 ± 4.36b,c	66.14 ± 5.81b,c
15f	4-ClC6H4	56.81 ± 23.23b,c	80.15 ± 3.75b,c	54.59 ± 10.20b,c
15g	4-OCH3C6H4	76.07 ± 22.49b,c	93.75 ± 3.20b	58.98 ± 11.75b,c
15h	3-ClC6H4	54.85 ± 23.48b,c	79.50 ± 5.89b,c	57.71 ± 6.44b,c
15i	2,4-Cl2C6H3	1.60 ± 6.90c	0.43 ± 6.28c	0.00 ± 9.34b,c
15j	2-C5H3S	82.32 ± 11.41b	93.31 ± 1.86b	68.46 ± 7.04 b,c
15k	2-C5H3O	96.18 ± 2.63b	98.42 ± 1.09b	81.31 ± 15.35b

Results are expressed as the mean ± S.D. percent growth inhibition of triplicate determinations and represent at least three different experiments. ^a10μM, ^bP < 0.05 vs. vehicle, ^cP < 0.001 vs. SAHA